NDC 66302-720 Tyvaso Dpi
Treprostinil Kit - View Dosage, Usage, Ingredients, Routes, UNII
Product Information
- 66302 - United Therapeutics Corporation
- 66302-720 - Tyvaso Dpi
Product Packages
NDC Code 66302-720-04
Package Description: 1 KIT in 1 PACKAGE * 4 INHALANT in 1 BLISTER PACK * 4 INHALANT in 1 BLISTER PACK
Product Details
What is NDC 66302-720?
What are the uses for Tyvaso Dpi?
Which are Tyvaso Dpi UNII Codes?
The UNII codes for the active ingredients in this product are:
- TREPROSTINIL (UNII: RUM6K67ESG)
- TREPROSTINIL (UNII: RUM6K67ESG) (Active Moiety)
Which are Tyvaso Dpi Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FUMARYL DIKETOPIPERAZINE (UNII: XB09609XSL)
What is the NDC to RxNorm Crosswalk for Tyvaso Dpi?
- RxCUI: 2602751 - treprostinil 16 MCG Inhalation Powder
- RxCUI: 2602751 - treprostinil 0.016 MG Inhalation Powder
- RxCUI: 2602754 - TYVASO DPI 16 MCG Inhalation Powder
- RxCUI: 2602754 - treprostinil 0.016 MG Inhalation Powder [Tyvaso]
- RxCUI: 2602754 - Tyvaso 0.016 MG Inhalation Powder
* Please review the disclaimer below.
Patient Education
Treprostinil Oral Inhalation
Treprostinil oral inhalation is used to treat certain kinds of pulmonary arterial hypertension (PAH; high blood pressure in the vessels carrying blood to the lungs, causing shortness of breath, dizziness, and tiredness). Treprostinil oral inhalation is also used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; high blood pressure in the lungs resulting from a lung disease that involves inflammation and scarring of the lungs). Treprostinil may improve the ability to exercise and slow the worsening of symptoms in patients with PAH and PH-ILD. Treprostinil is in a class of medications called vasodilators and platelet-aggregation inhibitors. It works by relaxing the blood vessels, including those in the lungs, and improving blood flow.
[Learn More]
* Please review the disclaimer below.
[1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
[3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.
[6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
[8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.
[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.
[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".